Please use the arrows to navigate to the sub pages
Futura Medical is a pharmaceutical company developing a portfolio of innovative products based on our proprietary, transdermal DermaSys® drug delivery technology.
Futura Medical is developing a portfolio of innovative products for two large markets, sexual health and pain.
Futura has a proven track record in delivery and completion of Research & Development projects up to value inflection points at which they are suitable for commercialisation partners.
Videos and audio
This section contains the latest RNS, news and videos.
The effect of the options, if all were exercised, would be to increase the issued share capital by 3.02% and raise £2,193,650 for the Company.
There are no restrictions on the transfer of Futura Medical plc shares.
Shareholders holding more than 3% of the share capital of Futura were:
In terms of the AIM Rules and insofar as it is aware, 16.73% of the Company's AIM securities are not in public hands.
In terms of the AIM Rules, there are no shares held in treasury.
The daily average number of shares traded since 2014 is:
The number of ordinary shares subject to options granted under the Share Option Schemes of the Company were:
Further details of share options issued can be obtained from the Company's Annual Report 2018 which can be found in the Corporate Documentation.